Protocol for Eslax Intravenous Drug Use Investigation (Study P06082)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Anesthesia

Treatments: Drug: Rocuronium

Study type: Observational

Funder types: Industry

Identifiers

NCT00902070

P06082

Details and patient eligibility

About

The main purpose of this investigation is to collect safety and efficacy information of Eslax Intravenous 25mg/2.5mL and 50mg/5.0mL (hereinafter referred to as "Eslax") in daily clinical settings.

Full description

Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.

Enrollment: 3,969 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients to whom Eslax has been administered to relax muscles at the time of anesthesia or tracheal intubation.

Exclusion criteria

• Patients with a history of hypersensitivity to Eslax or bromide.
• Patients with myasthenia gravis or myasthenic syndrome.

Trial design

3,969 participants in 1 patient group

1

Description:

Patients to whom Eslax has been administered to relax muscles at the time of anesthesia or tracheal intubation

Treatment:

Drug: Rocuronium